EP Patent

EP3679141A4 — METHODS AND COMPOSITIONS TO INHIBIT LDHA EXPRESSION

Assigned to Novo Nordisk Health Care AG · Expires 2021-06-16 · 5y expired

What this patent protects

Patent listed against nedosiran-sodium.

Drugs covered by this patent

Patent Metadata

Patent number
EP3679141A4
Jurisdiction
EP
Classification
—
Expires
2021-06-16
Drug substance claim
No
Drug product claim
No
Assignee
Novo Nordisk Health Care AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.